ENZON PHARMACEUTICALS INC Inactive Instrument
Enzon Pharmaceuticals Inc Stock Nasdaq
Equities
US2939041081
Biotechnology & Medical Research
|
End-of-day quote
Other stock markets
|
||
| - USD | - |
|
Financials (USD)
| Sales 2022 | 26K | Sales 2023 | - | Capitalization | 6.94M |
|---|---|---|---|---|---|
| Net income 2022 | - | Net income 2023 | 1M | EV / Sales 2022 | -1,103 x |
| Net cash position 2022 | 46.98M | Net cash position 2023 | 47.01M | EV / Sales 2023 | - |
| P/E ratio 2022 |
-12.5
x | P/E ratio 2023 |
70.9
x | Employees | - |
| Yield 2022 * |
-
| Yield 2023 |
-
| Free-Float | 89.16% |
More Fundamentals
* Assessed data
More news
More press releases
| Managers | Title | Age | Since |
|---|---|---|---|
| Chief Executive Officer | 80 | 13-12-12 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Randolph Read
CHM | Chairman | 71 | 20-08-03 |
| Director/Board Member | 67 | 22-06-30 | |
Jordan Bleznick
BRD | Director/Board Member | 68 | 20-08-03 |
Enzon Pharmaceuticals, Inc. (Enzon) is an acquisition vehicle company. The Company intends to become an acquisition platform. The Company utilizes its net operating loss carryforwards (NOLs) and improves stockholder value. It manages its source of royalty revenues from existing licensing arrangements with other companies.
| 1st Jan change | Capi. | |
|---|---|---|
| -3.10% | 102B | |
| +2.11% | 96.07B | |
| -1.80% | 21.66B | |
| -17.75% | 20.77B | |
| -6.91% | 18.53B | |
| -42.00% | 16.91B | |
| -28.19% | 13.79B | |
| +0.18% | 13.33B | |
| +19.90% | 10.94B |
